Compare Heron Therapeutics Inc (HRTX) vs i-80 Gold Corp. Common Shares (IAUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs i-80 Gold Corp. Common Shares — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $70.25M), while i-80 Gold Corp. Common Shares trades at $1.48 (market cap $1.26B). The key difference: i-80 Gold Corp. Common Shares is far larger — about 17.9× Heron Therapeutics Inc's market cap, and i-80 Gold Corp. Common Shares is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and i-80 Gold Corp. Common Shares for 0 Days on average.
| HRTX | IAUX | |
|---|---|---|
Market Cap | $70.25M | $1.26B |
Volume | 2,092,253 | 10,665,602 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $2.08 |
52-Week Low | $0.27 | $0.89 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $176.99M | $1.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $20.20 million on $154.90 million revenue in 2025, with a negative net income margin of -22.52%. Recent Q2 2026 earnings missed expectations, posting a loss of $0.03 per share versus an expected loss of $0.005. Analyst consensus remains strongly positive with 17 buy ratings out of 19 total.
The outlook is mixed; strong analyst support and improving cash flow trends in 2026 suggest potential, but persistent losses and high valuation multiples like EV/EBITDA of 34.03 pose significant risks. Investment opportunity hinges on future profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
IAUX trades at $1.54, down 2.53% today, with a neutral technical signal. The company shows significant financial challenges with a -198.82% net income margin and negative ROE of -71.66%, though revenue grew from $95M in 2025 to $130M in 2026. Recent positive developments include CEO purchasing 1 million shares and feasibility studies showing strong potential for Nevada gold projects. Analyst consensus remains unanimously bullish with 3 buy ratings.
While facing substantial profitability challenges, IAUX's development pipeline and CEO confidence suggest long-term potential. Key risks include persistent negative cash flow from operations and high debt levels. The stock presents a high-risk, high-reward opportunity dependent on successful project execution and gold price stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About i-80 Gold Corp. Common Shares
i-80 Gold Corp. is a mining company focused on developing and operating gold and precious-metals projects in Nevada, using a hub-and-spoke model centered on a processing facility to support multiple mine sites in the state.
Read more on IAUX →
